Thyroid-Stimulating Hormone (TSH) Peptides
Also known as: TSH analogs, Thyrotropin peptides, TSH receptor peptides
Overview
Thyroid-stimulating hormone (TSH/thyrotropin) is a 92 kDa glycoprotein pituitary hormone, but specific peptide fragments derived from its sequences have been studied as research tools and potential therapeutics. TSH receptor (TSHR) activating peptides have been investigated in models of thyroid function restoration and ophthalmopathy associated with Graves' disease. Additionally, TSH peptide fragments have been explored in immunology as tools to understand TSHR autoimmunity. This entry focuses on the concept of TSH-derived peptide research rather than native TSH itself.
Mechanism of Action
Specific peptide sequences from the TSH alpha or beta subunits can interact with TSHR or with autoantibodies (TRAbs) that drive Graves' disease. TSHR is a Gs-coupled GPCR activating adenylyl cyclase and cAMP-mediated thyroid hormone synthesis and secretion. Research has focused on identifying TSHR agonist peptides that could restore thyroid function without the immunogenic burden of recombinant protein TSH, and on TSHR antagonist peptides for Graves' disease management.
Potential Benefits
- Research tools for understanding TSHR autoimmunity in Graves' disease
- Potential TSHR-modulating peptide drugs avoiding full protein administration
- Insights into TSH receptor structure-function relationships
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | Clinical use only |
| Intermediate | N/A |
| Advanced | N/A |
| Cycle Duration | 2-day diagnostic/therapeutic course |
Thyrogen (thyrotropin alfa) FDA-approved for thyroid cancer monitoring and remnant ablation.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Intramuscular Injection High
Standard Thyrogen administration — gluteal IM.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Thyroid-Stimulating Hormone (TSH) Peptides:
Thyroid Cancer Follow-Up Protocol
Thyrogen-stimulated I-131 ablation or Tg monitoring for differentiated thyroid cancer — avoids thyroid hormone withdrawal.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate 2-8°C. After reconstitution, use within 24 hours (refrigerated). |
|---|
Clinical kit with supplied diluent.
Need exact syringe measurements?
Amino Acid Sequence
Various fragments of TSH alpha/beta chains under study
Side Effects & Safety
- Research context; systemic effects not established for fragments
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~25 hours (IM) |
|---|---|
| Storage | Refrigerate lyophilized product at 2-8°C. Protect from light. |
Synergistic Compounds
The following compounds have been studied alongside Thyroid-Stimulating Hormone (TSH) Peptides for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.